- Home
- MIN vs HUMA Comparison
MIN vs HUMA Comparison
Compare MIN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- HUMA
- Stock Information
- Founded
- MIN 1988
- HUMA 2004
- Country
- MIN United States
- HUMA United States
- Employees
- MIN N/A
- HUMA N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- MIN Finance
- HUMA Health Care
- Exchange
- MIN Nasdaq
- HUMA Nasdaq
- Market Cap
- MIN 303.8M
- HUMA 356.8M
- IPO Year
- MIN N/A
- HUMA N/A
- Fundamental
- Price
- MIN $2.68
- HUMA $2.40
- Analyst Decision
- MIN
- HUMA Strong Buy
- Analyst Count
- MIN 0
- HUMA 7
- Target Price
- MIN N/A
- HUMA $13.00
- AVG Volume (30 Days)
- MIN 331.0K
- HUMA 4.0M
- Earning Date
- MIN 01-01-0001
- HUMA 08-12-2025
- Dividend Yield
- MIN 7.31%
- HUMA N/A
- EPS Growth
- MIN N/A
- HUMA N/A
- EPS
- MIN 0.08
- HUMA N/A
- Revenue
- MIN N/A
- HUMA $517,000.00
- Revenue This Year
- MIN N/A
- HUMA N/A
- Revenue Next Year
- MIN N/A
- HUMA $858.42
- P/E Ratio
- MIN $33.38
- HUMA N/A
- Revenue Growth
- MIN N/A
- HUMA N/A
- 52 Week Low
- MIN $2.52
- HUMA $1.15
- 52 Week High
- MIN $2.88
- HUMA $9.79
- Technical
- Relative Strength Index (RSI)
- MIN 49.15
- HUMA 49.03
- Support Level
- MIN $2.63
- HUMA $2.44
- Resistance Level
- MIN $2.70
- HUMA $2.84
- Average True Range (ATR)
- MIN 0.02
- HUMA 0.20
- MACD
- MIN -0.00
- HUMA 0.00
- Stochastic Oscillator
- MIN 42.86
- HUMA 20.34
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.